| Project/Area Number |
17K06923
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biofunction/Bioprocess
|
|---|
| Research Institution | Kyoto Institute of Technology |
|---|
Principal Investigator |
Kumada Yoichi 京都工芸繊維大学, 分子化学系, 准教授 (70452373)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | scFv / RabMab / CDR-grafting / production / 抗体フラグメント / single-chain Fv / Fc融合タンパク質 / 抗体医薬 / HF-RabMab / Fc Engineering / scFv-Fc / Bioprocess |
|---|
| Outline of Final Research Achievements |
In this study, we demonstrated screening, production and CDR-grafting of a novel rabbit monoclonal antibody (RabMab), and also investigated a possibility of RabMab to use as a biologics. Antigen-specific RabMab clones were efficiently isolated by phage display system, and then, they were successfully produced in recombinant E. coli, Insect and animal cells with different fragment styles. CDR-grafting of RabMab was also possible. Thus we could confirm that RabMab has a great potential and usefulness to use in clinical trials.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では、抗原特異性ならびに親和性に定評のあるウサギモノクローナル抗体（RabMab）の単離技術、生産技術、特異性変換技術を確立することに成功した。その結果、あらゆる抗原に対するRabMabを自在に単離、生産することが可能となった。本研究成果は、医薬品開発や検査薬開発の迅速化・効率化に大きく貢献できると考えられる。
|
